Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 3:22 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1081–1104 of 1,610 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: FLD Clear all

Conditions: Rotator Cuff Tear
Interventions: Ivivi Torino II, Inactive Sham device; Device
Lead sponsor: Amp Orthopedics, Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 3
States / cities: New Orleans, Louisiana • Jackson, Mississippi • Taos, New Mexico

Conditions: Stimulant Use Disorder, Substance-related Disorders
Interventions: Repetitive transcranial magnetic stimulation (rTMS); Device
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Hernia
Interventions: acellular porcine dermal collagen mesh; Device
Lead sponsor: Medtronic - MITG; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 3
States / cities: Lexington, Kentucky • Albany, New York • Greenville, South Carolina

Conditions: Lipodystrophy
Interventions: Venus Versa, Glycerine gel; Device · Other
Lead sponsor: Venus Concept; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Fort Lee, New Jersey

Conditions: Non-hodgkin Lymphoma, Hodgkin Lymphoma
Interventions: DOC Group B, Pv-COMRAD 1 and 2 Group B, Pv-R-CYM 1 and 2 Group B, DOC Group C, MAD CPR 1 and 2, Pv-R CYVE 1 and 2, Pv-R CYVE-MTX 1 and 2, MAD CP, Pv-Cytarabine/etoposide, AD CP, Bv-AVD-R 1 and 2: COHORT IIa, Bv-NVD-R, Cycle 1-2, Bv-NVD-R, Cycle 1-4 SER, Bv-AVD-R, Bv-NVD-R, Cycle 1-4 RER, Bv-NAVD-R, Cycle 1-2, Involved Site Radiation Therapy; Drug · Radiation
Lead sponsor: New York Medical College; Other
Eligibility: 3 Years to 39 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 3
States / cities: Birmingham, Alabama • Gainsville, Florida • Vallhala, New York

Conditions: Traumatic Brain Injury
Interventions: rTMS, Amantadine; Device · Drug
Lead sponsor: Edward Hines Jr. VA Hospital; Federal
Eligibility: 18 Years to 64 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 2
States / cities: Chicago, Illinois • Hines, Illinois

Conditions: Bipolar Depression, Bipolar Disorder, Depression
Interventions: Echo-Planar Magnetic Resonance Imaging (EP-MRSI); Device
Lead sponsor: Mclean Hospital; Other
Eligibility: 18 Years to 70 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2012
U.S. locations: 1
States / cities: Belmont, Massachusetts

Conditions: Chronic Pain, Osteo Arthritis Knee
Interventions: Transcranial Magnetic Stimulation; Device
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Neural Bases of Speech Perception
Interventions: Transcranial Magnetic Stimulation; Device
Lead sponsor: University of Connecticut; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Storrs, Connecticut

Conditions: Androgenetic Alopecia
Interventions: Autologous platelet-rich plasma; Biological
Lead sponsor: Santiste Medical Inc.; Industry
Eligibility: 30 Years to 60 Years · Male only
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Burlington, Massachusetts

Conditions: Healthy
Interventions: Pulsed Electromagnetic Field therapy (PEMF), Pulsed Electromagnetic Field Sham therapy; Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 65 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Parkinson Disease
Interventions: Nighttime Deep Brain Stimulation with Varying Amplitude Settings; Other
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Substance Abuse, Suicide, Depression
Interventions: Repetitive Transcranial Magnetic Stimulation (rTMS), sham rTMS; Device
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 64 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Cervical Cancer, HIV
Interventions: DeepDOF Images; Device
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 25 Years to 49 Years · Female only
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Myocardial Infarction, Chest Pain
Interventions: Electrocardiogram (ECG) Intervention, Routine Clinical Practice; Device · Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 794 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Hodgkin's Lymphoma
Interventions: Adriamycin®, Vinblastine, Nitrogen Mustard, Cyclophosphamide, Vincristine, Bleomycin, Etoposide, Prednisone, G-CSF, Radiotherapy; Drug · Biological · Procedure
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 21 Years
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2022
U.S. locations: 6
States / cities: Palo Alto, California • San Diego, California • Portland, Maine + 2 more

Conditions: Complex Regional Pain Syndrome (CRPS)
Interventions: Transcranial Magnetic Stimulation (TMS); Device
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Esophageal Cancer
Interventions: filgrastim, pegfilgrastim, cisplatin, fluorouracil, paclitaxel, conventional surgery, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years to 120 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2016
U.S. locations: 97
States / cities: Burbank, California • Hayward, California • Mission Hills, California + 72 more

Conditions: Breast Cancer
Interventions: Selene; Device
Lead sponsor: Perimeter Medical Imaging; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 613 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 10
States / cities: Jacksonville, Florida • Tampa, Florida • Meadowbrook, Pennsylvania + 6 more

Conditions: Diabetic Retinopathy
Interventions: Aflibercept Injection; Drug
Lead sponsor: Greater Houston Retina Research; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 2
States / cities: Houston, Texas • The Woodlands, Texas

Conditions: Actinic Keratosis
Interventions: SOR007 (Uncoated Nanoparticulate Paclitaxel) Ointment, SOR007 Ointment Vehicle; Drug · Other
Lead sponsor: DFB Soria, LLC; Industry
Eligibility: 45 Years to 85 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Malignant Solid Neoplasm, Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Non-Small Cell Cancer AJCC v7
Interventions: 3-Dimensional Conformal Radiation Therapy, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Pembrolizumab, Proton Beam Radiation Therapy, Radiation Therapy, Stereotactic Body Radiation Therapy; Radiation · Other · Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Nicotine Use Disorder
Interventions: Active 10-Hz TMS to the DLPFC, Sham TMS-DLPFC; Device
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years to 55 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
Interventions: Bevacizumab, NovoTTF-l00A, Quality of Life Assessment; Biological · Device · Other
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 22 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 3
States / cities: Cincinnati, Ohio • Cleveland, Ohio

Search by objective public record fields.

Effectiveness of the Ivivi Torino II, Pulsed Radio Frequency Device, on Narcotic Use, Pain and Quality of Life Following Shoulder Arthroscopic Rotator Cuff Repair.

Treating Stimulant Addiction With Repetitive Transcranial Magnetic Stimulation

Feasibility of Permacol Use in Infected Fields

Clinical Evaluation of Venus Versa Octipolar Applicator for Reduction of Abdomen Circumference

Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma

Amantadine + rTMS as a Neurotherapeutic for Disordered Consciousness

Low Field Magnetic Stimulation Treatment for Bipolar Depression

rTMS for Relieving Chronic OA Pain

Left and Right Hemisphere Contributions to Speech Perception

Activated PRP for Treatment of Androgenetic Alopecia

Ultramarathons and Impact of Phased Electromagnetic Field Therapy (PEMF)

Deep Brain Stimulation Neural Recordings of Varied Stimulation During Sleep in Parkinson's Disease

Functional Connectivity Alterations in Suicidal Patients Among Opioid Users

Evaluation of a Novel Optical Microscope With a Deep Depth of Field (DeepDOF) to Provide Histologic-quality Images on Cervical Biopsies and Loop Electrosurgical Excision Procedure (LEEP) Specimens at the Point-of-care

Tele-Electrocardiography in Emergency Cardiac Care

Chemotherapy With Low-Dose Radiation for Pediatric Hodgkin Lymphoma

Transcranial Magnetic Stimulation (TMS) for CRPS

Combination Chemotherapy Followed By Chemoradiotherapy, With or Without Surgery, in Treating Patients With Resectable Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction

Wide Field OCT + AI for Positive Margin Rates in Breast Conservation Surgery.

Intravitreal Aflibercept as Indicated by Real-Time Objective Imaging to Achieve Diabetic Retinopathy Improvement

Study of SOR007 Ointment for Actinic Keratosis

Pembrolizumab and Stereotactic Body Radiation Therapy or Non-Stereotactic Wide-Field Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer

Identify the Optimal TMS Target to Modulate Reward Activity

NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma